EDISON

Cereno Scientific

First patient, fresh momentum

Clinical update

Healthcare

19 November 2026

Cereno Scientific has reached an inflection point in its clinical development, with the first patient randomised and dosed in the Phase IIb EPIMODE study of CS1 in pulmonary arterial hypertension (PAH). This marks an encouraging transition into active treatment, following a slower-than-anticipated start to patient randomisation. Importantly, management has maintained its target of completing recruitment in 2027, with top-line results expected in Q428, suggesting limited impact on the broader development timeline. EPIMODE represents the critical clinical validation step for CS1, with its extended 52-week treatment duration and two-stage design offering an opportunity to demonstrate sustained efficacy and potential disease modification, a key differentiator in PAH. With clinical activities gathering momentum and the proposed financing package offering a potential funding pathway, we believe these developments should help rebuild investor confidence and support a more constructive outlook for Cereno.

Year end	Revenue (SEKm)	PBT (SEKm)	EPS (SEK)	DPS (SEK)	P/E (x)	Yield (%)
12/24	0.0	(98.1)	(0.35)	0.00	N/A	N/A
12/25	0.0	(117.8)	(0.38)	0.00	N/A	N/A
12/26e	0.0	(113.4)	(0.35)	0.00	N/A	N/A
12/27e	0.0	(124.5)	(0.38)	0.00	N/A	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.


The first-patient dosing milestone follows activation of the initial clinical site in August 2026. EPIMODE is a global, randomised, double-blind, placebo-controlled Phase IIb study designed to enrol c 126 patients across 68 sites in 12 countries. CS1, Cereno's lead asset, is an oral, once-daily histone deacetylase (HDAC) inhibitor being evaluated as an add-on to standard of care in PAH. The primary endpoint is change in pulmonary vascular resistance (PVR) after nine months, alongside assessments of right-heart function, clinical outcomes and safety. Notably, EPIMODE incorporates a two-stage design, with patients re-randomised after the initial 36-week treatment period to assess the durability of treatment effects, potentially providing further evidence of disease modification.

The study builds on encouraging Phase IIa findings, including improvements in right-heart function, functional class and quality of life, alongside signals consistent with reverse vascular remodelling. The expanded access programme reinforced CS1's favourable safety profile, extending treatment duration to c 15 months. However, these findings remain exploratory, and EPIMODE will be critical in establishing whether the benefits translate into statistically robust efficacy in a controlled population. We see the PVR endpoint and treatment durability assessments as central to validating CS1's differentiation.

Management expects up to 15 clinical sites to be activated by end-2026, increasing to more than half the network by end-Q127. Recruitment momentum therefore will be crucial to meeting the targeted 2027 completion. On financing, the proposed SEK400m rights issue could prove challenging at the depressed share price, although Cereno could explore strategic partnerships or alternative funding arrangements, while prioritising EPIMODE over earlier-stage programmes if necessary. We believe the latest clinical progress could strengthen investor confidence and support financing efforts, although funding visibility remains a key consideration. We retain our existing clinical assumptions pending further progress.

Price	**SEK0.14**
Market cap	**SEK45m**
	SEK9.30/US$
Net cash/(debt) at end-September 2026	SEK(134.8)m
Shares in issue	323.9m
Free float	93.0%
Code	CRNO B
Primary exchange	NGM
Secondary exchange	N/A

Share price performance



Business description

Cereno Scientific is a clinical-stage biotech based in Sweden, focused on the development of innovative, effective and safe treatments for indications with high unmet needs. Lead asset CS1 is an HDAC inhibitor that acts as an epigenetic modulator. The first patient was dosed in the Phase IIb study in PAH in November 2026 with top-line data anticipated by Q428. Second asset CS014, a proprietary NCE and HDACi, is being developed for PH-ILD, and preclinical asset CS585's lead target indication is antiphospholipid syndrome, a rare autoimmune condition.

Analysts

Jyoti Prakash, CFA +44 (0)20 3077 5700

Arron Aatkar, PhD +44 (0)20 3077 5700

healthcare@edisongroup.com

Edison profile page

Cereno Scientific is a research client of Edison Investment Research Limited

General disclaimer and copyright

This report has been commissioned by Cereno Scientific and prepared and issued by Edison, in consideration of a fee payable by Cereno Scientific. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London | New York | Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom